Effects of Bifidobacterium and rosuvastatin on metabolic-associated fatty liver disease via the gut–liver axis
The combined use of Bifidobacterium and rosuvastatin could better regulate the gut microbiota of MAFLD model rats, promote gastrointestinal emptying, and improve liver pathology and function than single treatment with Bifidobacterium or rosuvastatin. This provides a better strategy for the treatment of MAFLD.
Authors
- Chibing Dai
- Xue Ran (ORCID: https://orcid.org/0000-0002-9974-8574)
- Shigang Li (ORCID: https://orcid.org/0000-0003-0022-7865)
- Yingjie Wang (ORCID: https://orcid.org/0000-0002-1352-6752)
Institutions
- China Three Gorges University (CN)
- Xiang Yang No.1 People's Hospital (CN)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12944-024-02391-8
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Health Commission of Hubei Province